Nov 4. 2021
KaliVir Immunotherapeutics Strengthens Intellectual Property Position Through Issuance of Two U.S. Patents.
December 7. 2020
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus.
How Stephen Thorne and Helena Chaye are blending their talents to create Breakthrough cancer fighting therapies
June 17. 2021
KaliVir Immunotherapeutics appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors